McKesson Corporation (MCK) Financial Ratios

McKesson Corporation (MCK) has an ST Score of 62.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate MCK a Buy, with a price target of $983.13 (-4.6% vs the current price). Our ST Score grades it B (62.7/100). The ST Score is a data-driven signal, not a recommendation.

Valuation D+, Profitability B+, Financial Strength B, Momentum A, Growth A-, Forecast C+, Sentiment C+.

McKesson Corporation (MCK) earns a valuation grade of D+, measured against Medical - Distribution peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

McKesson Corporation (MCK) earns a growth grade of A-, measured against Medical - Distribution peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

McKesson Corporation (MCK) earns a profitability grade of B+, measured against Medical - Distribution peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

McKesson Corporation (MCK) earns a financial strength grade of B, measured against Medical - Distribution peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for McKesson Corporation (MCK) is $983.13 from 31 analysts, which is -4.6% versus the recent price of $1030.12.

McKesson Corporation (MCK) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.